NCT00294671View on ClinicalTrials.gov

The Effect of Diflunisal on Familial Amyloidosis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Familial Amyloid PolyneuropathyFamilial Amyloidosis
Interventions
DRUG

diflunisal

given twice daily for 24 months

OTHER

placebo

an inactive substance given twice daily for 24 months

Trial Locations (8)

27100

IRCCS Policlinico San Matteo, Pavia

55905

Mayo Clinic Rochester, Rochester

02118

Amyloidosis Center, Boston Medical Center, Boston

10029-6574

Mount Sinai School of Medicine, Department of Medicine, New York

860-0811

Kumamoto University, Kumamoto

390-8621

Shinshu University, Matsumoto

SE-901 86

Umea University Hospital, Umeå

SE5 9RS

King's College Hospital, London

All Listed Sponsors
collaborator

Food and Drug Administration (FDA)

FED

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Boston University

OTHER

NCT00294671 - The Effect of Diflunisal on Familial Amyloidosis | Biotech Hunter | Biotech Hunter